Indian scientists testing dendritic therapy against cervix cancer

Researchers at the National Institute of Immunology (NII) have identified a tumour antigen that promises to be a potent weapon in combating cervical cancer
New Delhi: Cancer of the uterine cervix, also known as cervical cancer, is the second leading cause of cancer deaths among women in India. Almost one lakh women fall victim to the insidious disease every year in the country.
Researchers at the New Delhi-based National Institute of Immunology (NII) are in the process of fine tuning a solution that promises to add a highly potent weapon to the armoury against this type of cancer. They have extracted and identified a tumour antigen which seems to hold a lot of promise. The antigen has been named SPAG9.
“The tumor antigen, which is expressed in reproductive tract cancers and a variety of malignancies, has proved successful in phase I trials. This means it has been proved to be safe on human subjects. Phase II clinical trials are presently underway to gauge its efficacy. We hope to get positive results by next year,” said Dr Anil Kumar Suri, NII director, in an interview.
The therapeutic vaccine based on the antigen is being tested among 54 patients at Cancer Institute (WIA) at Adyar in Chennai. The trials are being conducted by a team of oncologist led by Dr T. Rajkumar. If proven efficacious, it could change the face of cervix cancer treatment. The human trials are being conducted subsequent to elaborate trials with animal models.
Invasion of foreign bodies like bacteria or virus usually trigger a volley of fighter cells called T cells. These T cells surround germs and fight them. Each type of virus or bacteria requires specific antigen T cells. Vaccination primes the body to potential threats and keeps the arsenal of antigens ever ready to fight an invasion.
However, this cannot happen with cancer. Even though they are rogue elements, cancer cells are after all from within the affected persons themselves. Body’s immune system cannot normally recognize them as a ‘threat’. They, therefore, allow them to proliferate and spread all around the body.
Immunotherapy is a new approach that exploits body’s inner capability to put up a fight against cancer. Under the approach, either immune system is given a boost or the T cells are “trained’’ to identify recalcitrant cancer cells and kill them.
The NII scientists are using this strategy to develop the new weapon against cancer of the cervix.  “We take cells called monocytes from the patient’s blood and modify them into what are called dendritic cells. These cells have efficient antigens to stimulate the ‘fighter’ cells, or T-cells, in the body. They are then primed with the tumour antigen SPAG9, for ten days, and given back to the patients in the form of a vaccine. The ‘educated’ T cells are able to discriminate the cancer cells and put up a fight against them,” explained Dr Suri.
Poor health, malnutrition, unhygienic environment are the main cause of Human papillomavirus (HPV) infection that leads to cervical cancer. Normally our body has tumor suppressor genes and proteins which are able to suppress formation of tumours. The cells in a tumour multiply uncontrollably with hardly any cell death.
NII has outsourced the manufacture of recombinant SPAG9 to Syngene International (Biocon Limited), Bangalore. “If the trials succeed, it will be the first molecule identified in India and will be an example of translational research outcome. Our findings have opened new avenues for novel treatment modalities in battling the deadly disease of cancer worldwide,” said Dr Suri.
Dr. Suri graduated from Hans Raj College, Delhi University and after that did his post-graduation and doctorate from National Dairy Research Institute at Karnal. Subsequently, he did his post- doctorate from Laboratoire pour le contrôle des Reproducteurs, Maisons-Alfort, France. He returned to India in 1985 and joined NII as a scientist.
The thrust of his research is on early detection and diagnosis of cancer and development of targeted approaches for therapeutic interventions for cancer medicine.
Dr Suri has authored 63 high impact publications in reputed international journal and has 15 patents on novel immunotherapeutic method for cancer treatment and diagnosis in India and abroad. He has won the S.S. Guraya Memorial Award, Dr T C Anand Kumar Memorial Oration Award and Rabindra Nath Chakravarti Citation Award.
Source:http://www.apnlive.com/technology-news/indian-scientists-testing-dendritic-therapy-against-cervix-cancer-27641

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more